NHS sponge test for oesophageal cancer backed by NICE

People in England who live with bad, persistent indigestion could soon be offered a simple sponge test at their GP surgery to check for early signs of cancer of the food pipe, under new draft guidance from the National Institute for Health and Care Excellence (NICE).
The test takes only a few minutes and is far less invasive than the hospital procedure it would partly replace. It is already available in some parts of the country, and the draft guidance would see it offered more widely across England, with final recommendations expected in the new year.
How the sponge test works
The patient swallows a small capsule attached to a fine thread. Once the capsule reaches the stomach it dissolves and releases a tiny sponge, which is then gently drawn back up through the gullet and out of the mouth. As it travels, the sponge picks up cells from the lining of the oesophagus, and those cells can then be examined for changes that might point to cancer.
The test does not require sedation and can be carried out in primary care facilities and community diagnostic centres, rather than in hospital. It can pick up both oesophageal cancer and a condition called Barrett's oesophagus, in which the cells lining the gullet have started to change after long exposure to stomach acid.
What NICE recommends
NICE's independent committee has recommended two capsule sponge tests, Cytosponge, made by Medtronic, and EndoSign, made by Cyted Health, to help detect oesophageal cancer and Barrett's oesophagus in people with persistent gastro-oesophageal reflux disease, commonly known as acid reflux.
The draft recommendations also give people already diagnosed with Barrett's oesophagus another option for monitoring their condition. The tests could be used as part of a surveillance programme to check periodically for cellular changes that may indicate oesophageal cancer.
The recommendations are the first to be produced through the National HealthTech Access Programme, a new approach designed to identify high-impact medical technologies that, if recommended by NICE, will be funded by the NHS and made consistently available to all eligible patients across the country. The programme is part of the government's 10 Year Health Plan.
Why it matters
Professor Jonathan Benger, the chief executive of NICE, described the sponge test as a quick, less invasive way to detect concerning changes and to identify people who should go on to have further tests and treatment.
Professor Peter Johnson, the national clinical director for cancer at NHS England, said the health service is always looking for better ways to get to the bottom of people's symptoms, and that thousands of people had already benefited through pilot schemes. "It's fantastic it is now being considered for roll out across the country," he said.
Finding oesophageal cancer earlier matters because treatment is more effective when the disease is caught at an early stage, before it has spread. A test that can be done at a GP surgery, without sedation or a hospital visit, lowers the barrier to being checked.
An important caution
The guidance also carries an important caution. No diagnostic test, including endoscopy, identifies every case, and NICE says people who receive a clear result from a sponge test should still be monitored over the long term rather than being discharged and forgotten.
Anyone with persistent, severe indigestion or difficulty swallowing should speak to their GP rather than waiting for the new guidance. The test is not a replacement for medical advice, and a clear result is not a guarantee.
What happens next
Comments can be made on the draft guidance through the NICE website until 7 December 2026. The independent committee will meet again on 16 December 2026 to consider the consultation responses, before making its final recommendations, which will be issued for appeal in final draft guidance during January 2027.
If the recommendations are confirmed in final guidance due during February 2027, the NHS in England will be required to begin delivery of the technology, including specialist staff training across the country, when a capsule sponge test is considered the most suitable option for the person.